Glenmark Pharma - Life Sciences Unit Stake Sale To Drive Considerable De-Leverage: Motilal Oswal

Earnings neutral event

<div class="paragraphs"><p>Glenmark Pharmaceutical Ltd.'s manufacturing facility in Indore. (Source: Company website)</p></div>
Glenmark Pharmaceutical Ltd.'s manufacturing facility in Indore. (Source: Company website)

BQ Prime’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BQ Prime’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

Motilal Oswal Report

Glenmark Pharmaceuticals Ltd. has proposed to divest its active pharma ingredient business, Glenmark Life Sciences Ltd. with the aim of reducing debt and increasing its emphasis on branded/innovative products.

This is the third transaction by Glenmark Pharma with a cumulative cash generation of Rs 62.5 billion over the past 12-15 months.

After the stake sale, Glenmark Pharma is set to transition from a net debt position of Rs 29.5 billion to a cash surplus Rs 21 billion.

The net reduction in overall Ebitda due to the sale of API business (Rs 5.5 billion) would be partially offset by a reduction in interest (Rs 4.2 billion).

Expecting significant deleveraging and superior execution in both the domestic formulation and Europe/rest of world markets, we anticipate an improved outlook for Glenmark Pharma over the next two-three years, which should positively impact return ratios to some extent.

We value Glenmark Pharma at 14 times 12 months forward earnings to arrive at a price target of Rs 780.

We maintain our 'Neutral' rating, given that the current valuation adequately captures potential earnings upside/better return ratios.

Click on the attachment to read the full report:

Motilal Oswal Glenmark Update.pdf
Glenmark Agrees To Sell 75% In Life Sciences Unit To Nirma For Rs 5,652 Crore


This report is authored by an external party. BQ Prime does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BQ Prime.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.